As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

ARQIT QUANTUM INC (ARQQ:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an established biological target in dermatology. It is also developing roflumilast cream for the treatment of atopic dermatitis. ZORYVE is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions. 

ARCUTIS BIOTHERAPEUTICS INC

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

ArQule, Inc.

Arqit Quantum Inc. is a United Kingdom-based quantum encryption technology company. The Company supplies a quantum encryption platform-as-a-service which makes the communications links of any networked device secure against current and future forms of attack such as attack from a quantum computer. The Company’s product, QuantumCloud, is a cloud delivered symmetric key agreement platform as a service. QuantumCloud enables any device to download a lightweight software agent of less than 200 lines of code, which can create encryption keys in partnership with any other device. The keys are computationally secure, one-time use and zero trust. QuantumCloud can create limitless volumes of keys in limitless group sizes and can regulate the secure entrance and exit of a device in a group. Its product, TradeSecure, generates and distributes digital trade finance instruments, protecting finance supply chains against disruption and fraud.

ARQIT QUANTUM INC

Tellurian Inc. is engaged in building a global natural gas business. The Company is engaged in developing and operating a portfolio of natural gas, liquefied natural gas (LNG) marketing, and infrastructure assets that includes an LNG terminal facility (the Driftwood terminal), an associated pipeline, other related pipelines, and upstream natural gas assets. The Company's segments include Upstream segment, Midstream segment, Marketing & Trading segment. The Upstream segment is organized and operates to produce, gather, and deliver natural gas and to acquire and develop natural gas assets. The Midstream segment is organized to develop, construct, and operate LNG terminals and pipelines. The Marketing & Trading segment is organized and operates to purchase and sell natural gas produced primarily by the Upstream segment, market the Driftwood terminal’s LNG production capacity and trade LNG.

Tellurian Inc.

Senseonics Holdings, Inc. is a medical technology company. The Company is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. It is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.

Senseonics Holdings, Inc.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. It uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Technologies Inc

Denison Mines Corp. is a uranium exploration and development company. The Company is engaged in the acquisition, exploration and development of uranium properties, extraction, processing and selling of uranium. The Company operates in three segments: the Mining segment, the Closed Mine Services segment and the Corporate and Other segment. The Mining segment includes activities related to exploration, evaluation and development, mining, milling (including toll milling) and the sale of mineral concentrates. The Closed Mine Services segment includes the operations of the Company’s environmental services business which provides mine decommissioning and other services. The Corporate and Other segment includes its provision of general administrative and management services to uranium participation corporation (UPC). It has interest in Wheeler River Uranium Project, McClean Lake uranium mill, Waterbury Lake property, Millennium project, the Kiggavik project, Christie Lake and Elliot Lake.

Denison Mines Corp

Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.

Back

ARQQ

Buy

👑 Overview

📈

-20.66%

Annual Growth

🌏

1

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$1.36

How our community is investing

1

N/A

N/A

N/A

994 days

ARQQ investor breakdown

💵 Income of investors

100%

👶 Age of investors

100%

🙋 Legal gender of investors

100%

$1.27 USD

Find Out More

$0.67 USD

Find Out More

$5.65 USD

Find Out More

$1.06 USD

Find Out More

$32.44 USD

Find Out More

$8.40 USD

Find Out More

$20.00 USD

Find Out More

Buy